Ablynx deal with Novartis extended; BI milestone

16 February 2009

Ghent, Belgium-based Ablynx, a pioneer in the discovery and development of Nanobodies, a novel class of antibody-derived therapeutic proteins,  says that its drug discovery and development alliance with Swiss drug  major Novartis has been extended for another year.

Under the terms of the agreement, entered into in December 2005, the  companies are collaborating to discover and develop novel Nanobody-based  therapeutics against disease targets that are difficult to address with  conventional antibodies or their fragments. Novartis has exclusive  rights to develop and commercialize the products resulting from the  collaboration.

This agreement was previously extended in December 2007 and, based on  the positive progress made, the companies have mutually agreed to extend  their alliance for another year. As part of the collaboration Ablynx  receives license fees and funding for research and development. In  addition, it is eligible for milestone payments and royalties upon  commercialization.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight